Diab Tamer, Fathi Abdallah, El-Dakhakhny Amr S, Abou Elezz Ahmed
Urology Department, Faculty of Medicine, Benha University, Benha, Egypt.
Arab J Urol. 2024 Sep 16;23(2):124-130. doi: 10.1080/20905998.2024.2403274. eCollection 2025.
To assess efficacy and safety of silodosin, tadalafil, versus combination of both medications as medical expulsive therapy (MET) for distal ureteric stones.
This prospective, double blinded, randomized clinical trial included 128 patients aged 18 years or more irrespective of gender who are presented to emergency department or outpatient with distal ureteric stones ranging in size from 5-10 mm, randomized into three groups: Group I ( = 42) received Silodosin 8 mg once daily, Group II ( = 44) received Tadalafil 5 mg once daily, and Group III ( = 42) received Silodosin 8 mg combined with Tadalafil 5 mg one daily. All participants underwent thorough history-taking, routine laboratory investigations, and clinical examinations.The primary end point included expulsion rate and time and treatment tolerance. Secondary end points were number pain episodes, need for emergency room visit, amount of analgesia, need for intervention.
The expulsion rate was 71.4% for silodosin, 61.4% for tadalafil and 88.1% for combined therapy ( = 0.018). Expulsion time was significantly shorter after combined therapy 10.4 + 3.5 days, while after silodosin 14.1 + 4 days, while 17.8 + 3.4 days after tadalafil ( < 0.001). The number of pain episodes, emergency room visits, and the amount of analgesia were significantly in favour of combined therapy ( value 0.004, 0.010, and <0.001) respectively.
A combination of Silodosin with Tadalafil as a MET for distal ureteric stones is more effective than monotherapy with tolerable side effects.
评估西洛多辛、他达拉非以及二者联合用药作为药物排石疗法(MET)治疗远端输尿管结石的疗效和安全性。
这项前瞻性、双盲、随机临床试验纳入了128例年龄在18岁及以上、性别不限、因远端输尿管结石(大小为5 - 10毫米)就诊于急诊科或门诊的患者,随机分为三组:第一组(n = 42)每日服用一次8毫克西洛多辛;第二组(n = 44)每日服用一次5毫克他达拉非;第三组(n = 42)每日服用一次8毫克西洛多辛与5毫克他达拉非的组合。所有参与者均接受了全面的病史采集、常规实验室检查和临床检查。主要终点包括排石率、排石时间和治疗耐受性。次要终点为疼痛发作次数、急诊就诊需求、镇痛剂量、干预需求。
西洛多辛组的排石率为71.4%,他达拉非组为61.4%,联合治疗组为88.1%(P = 0.018)。联合治疗后排石时间显著缩短,为10.4 ± 3.5天,西洛多辛组为14.1 ± 4天,他达拉非组为17.8 ± 3.4天(P < 0.001)。疼痛发作次数、急诊就诊次数和镇痛剂量方面,联合治疗组均显著占优(P值分别为0.004、0.010和<0.001)。
西洛多辛与他达拉非联合作为远端输尿管结石的药物排石疗法比单一疗法更有效,且副作用可耐受。